Stifel Nicolaus Raises Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $40.00

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective upped by Stifel Nicolaus from $37.00 to $40.00 in a research note issued to investors on Tuesday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating on the medical device company’s stock.

A number of other research firms also recently commented on TNDM. StockNews.com raised Tandem Diabetes Care from a sell rating to a hold rating in a report on Friday, April 19th. Citigroup increased their price target on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a neutral rating in a research report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $39.45.

Tandem Diabetes Care Trading Up 1.3 %

TNDM stock opened at $35.56 on Tuesday. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $40.74. The stock has a 50-day simple moving average of $30.74 and a 200-day simple moving average of $25.26.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $196.80 million during the quarter, compared to analysts’ expectations of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. Sell-side analysts forecast that Tandem Diabetes Care will post -1.62 EPS for the current year.

Institutional Trading of Tandem Diabetes Care

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Tandem Diabetes Care by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company’s stock valued at $207,708,000 after acquiring an additional 18,571 shares during the period. Eminence Capital LP increased its position in Tandem Diabetes Care by 76.1% in the 3rd quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock valued at $114,028,000 after acquiring an additional 2,372,458 shares during the period. Paradice Investment Management LLC increased its position in Tandem Diabetes Care by 23.9% in the 3rd quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company’s stock valued at $31,572,000 after acquiring an additional 293,250 shares during the period. Jennison Associates LLC increased its position in Tandem Diabetes Care by 14.9% in the 4th quarter. Jennison Associates LLC now owns 1,290,590 shares of the medical device company’s stock valued at $38,176,000 after acquiring an additional 167,675 shares during the period. Finally, GW&K Investment Management LLC acquired a new stake in Tandem Diabetes Care in the 4th quarter valued at approximately $36,288,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.